54110-88-2

Basic information

• Product Name: Benzene, 1-ethoxy-2-methoxy-4-(2-nitroethenyl)-
• CAS NO: 54110-88-2
• Molecular Formula: C11H13NO4
• Molecular Weight: 223.229
• Mol File: 54110-88-2.mol

Chemical Properties

• CAS DataBase Reference: Benzene, 1-ethoxy-2-methoxy-4-(2-nitroethenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-ethoxy-2-methoxy-4-(2-nitroethenyl)-(54110-88-2)
• EPA Substance Registry System: Benzene, 1-ethoxy-2-methoxy-4-(2-nitroethenyl)-(54110-88-2)

Safety Data

• Hazardous Substances Data: 54110-88-2(Hazardous Substances Data)

Upstream product

• 75-52-5 nitromethane 
• 120-25-2 4-ethoxy-3-methoxybenzaldehyde 
• 121-33-5 vanillin 

Downstream Products

• 36377-59-0 2-(4-ethoxy-3-methoxyphenyl)ethylamine 
• 15992-73-1 6β-Dinitro-3-methoxy-4-ethoxy-styrol 
• 1448014-02-5 (S)-2-[(R)-1-(4-ethoxy-3-methoxyphenyl)-2-nitroethyl]cyclohexanone 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein and its deficiency markedly enhanced the survival rate of patient with cardiovascular diseases (CVDs). Forty berberine (BBR) derivatives were synthesized and evaluated for their activities on down-regulating the transcription of PCSK9 in HepG2 cells, taking BBR as the lead. Structure–activity relationship (SAR) analysis revealed that 2,3-dimethoxy moiety might be beneficial for activity. Among them, 9k displayed the most potent activity with IC50 value of 9.5 ± 0.5 μM, better than that of BBR. Also, it significantly decreased PCSK9 protein level at cellular level, as well as in the liver and serum of mice in vivo. Furthermore, 9k markedly increased LDLR expression and LDL-C clearance via down-regulating PCSK9 protein. The mechanism of action of 9k is targeting HNF1α and/or Sp1 cluster modulation upstream of PCSK9, a different one from BBR. Therefore, 9k might have the potential to be a novel PCSK9 transcriptional inhibitor for the treatment of atherosclerosis, worthy for further investigation.

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.